1-32797768-C-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_003680.4(YARS1):c.586G>A(p.Glu196Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E196G) has been classified as Uncertain significance.
Frequency
Consequence
NM_003680.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
YARS1 | NM_003680.4 | c.586G>A | p.Glu196Lys | missense_variant | 5/13 | ENST00000373477.9 | NP_003671.1 | |
YARS1 | XM_011542347.3 | c.-45G>A | 5_prime_UTR_variant | 3/11 | XP_011540649.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
YARS1 | ENST00000373477.9 | c.586G>A | p.Glu196Lys | missense_variant | 5/13 | 1 | NM_003680.4 | ENSP00000362576.4 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Charcot-Marie-Tooth disease dominant intermediate C Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 2006 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 13, 2023 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Glu196 amino acid residue in YARS. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 26257172). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects YARS function (PMID: 19561293, 26138142, 26975778). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt YARS protein function. ClinVar contains an entry for this variant (Variation ID: 6189). This missense change has been observed in individual(s) with dominant intermediate Charcot-Marie-Tooth disease, type C (PMID: 14606043, 16429158). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 196 of the YARS protein (p.Glu196Lys). - |
Neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Sep 15, 2023 | - - |
Charcot-Marie-Tooth disease Uncertain:1
Uncertain significance, no assertion criteria provided | literature only | Inherited Neuropathy Consortium | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at